Brief: Biomerieux Q1 Sales EUR 984 Million

Biomerieux SA

23/04/2026 06:25

April 23 (Reuters) - Biomerieux SA BIOX.PA:

-3.9% ORGANIC SALES DECLINE IN Q1 2026

CONFIRMATION OF A FULL‑YEAR CEBIT HEADWIND FROM CURRENCY EFFECT OF -€50M TO - €60M

REVISES ITS 2026 FULL-YEAR GUIDANCE: ANNUAL SALES ARE NOW EXPECTED TO GROW ORGANICALLY BETWEEN +3% TO +5% (VERSUS BETWEEN +5% AND +7% PREVIOUSLY)

REVISES ITS 2026 FULL-YEAR GUIDANCE: ANNUAL CEBIT IS EXPECTED TO GROW ORGANICALLY BETWEEN 0% AND 10% (VERSUS AT LEAST +10% PREVIOUSLY) EXCLUDING A PROLONGED IMPACT OF MIDDLE EAST EVENTS

REVISED FY GUIDANCE: ANNUAL SALES NOW EXPECTED TO GROW ORGANICALLY BETWEEN +3% TO +5% (VERSUS BETWEEN +5% AND +7% PREVIOUSLY)

CONFIRMATION OF A FULL‑YEAR CEBIT HEADWIND FROM CURRENCY EFFECT OF -€50M TO - €60M.

Q1 SALES EUR 984 MILLION

WILL MAINTAIN STRICT AND DISCIPLINED CONTROL OF OUR COST BASE, TO ENSURE A POSITIVE ORGANIC EVOLUTION OF CEBIT IN 2026 - CEO

Source text: [ID:]

Further company coverage: BIOX.PA

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))